HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Genomic navigators key to proper interpretation of sequencing data
-
- Results demonstrate ‘ongoing need for improvement’ in gastric cancer treatment David H. Ilson, MD, PhD
- Response-adapted therapy of lymphoma: Real progress or really confusing? John Sweetenham, MD, FRCP, FACP
- State of the science: High-priority transplant trials for AML, MDS William Wood, MD
- Pre-existing diabetes increased mortality rate in patients with cancer
- Testicular germ cell tumor incidence increased in Hispanic adolescents, young adults
- Gene expression in adjacent airways may help detect early lung cancer
- Black women less likely to undergo SLNB for breast cancer
- Co-expression of cancer stem cells, tumor-associated macrophages predicted pancreatic cancer survival
-
- Inadequate lymph node staging common in gastric adenocarcinoma
- Modified blood stem cell transplant reversed sickle cell disease in adults
- Neutrophil-to-lymphocyte ratio improved accuracy of prognostic score for castration-resistant prostate cancer
- Noninvasive ultrasound reduced pain from bone metastases
- Radiation therapy controlled progression in crizotinib-treated ALK-positive NSCLC
- Mammography screening costs varied by $8 billion per strategy
- Drug development expert joins Yale
- Neuroblastoma Research Association presents lifetime achievement award
-
- ONS announces board of directors
- St. Jude announces CEO appointment
- Physician receives Blue Ribbon Award from Integrated Medical Foundation
- Necitumumab plus chemotherapy improved PFS, OS in squamous NSCLC
- HPV-targeted T-cell therapy shows promise for advanced cervical cancer
- Ipilimumab plus nivolumab demonstrated encouraging activity in advanced melanoma
- Lenvatinib improved PFS in radioiodine-resistant differentiated thyroid cancer
- Temsirolimus combination improved event-free survival in rhabdomyosarcoma
-